VALLADOLID, 29 Feb. (EUROPA PRESS) –
The Governing Council has approved two agreements for a total amount of 5,704,103 euros for the purchase of 125,000 units of the 15-valent pneumococcal conjugate vaccine, which extends protection in the child population, and 20-valent, which It is administered at age 65, within the guidelines established by the Community calendar.
Pneumococcus is transmitted through the air or by direct exposure to respiratory particles from people infected or carrying the bacteria. It usually has a higher incidence in winter or early spring, when respiratory pathologies are more frequent, explains the Board in a statement.
In this sense, and with the aim of covering the vaccination guidelines set in the official calendar of the Community, the Board has acquired 60,000 doses of the 15-valent conjugate pneumococcal vaccine with a budget of 2,727,270 euros.
“With this new vaccine, protection against pneumococcus serotypes in the child population is improved by incorporating the 15-serotype pneumococcal conjugate vaccine into the calendar to replace the 13-serotype pneumococcal conjugate vaccine. The same three-dose schedule is maintained by inoculating it at 2,4 and 11 months. It will begin with the cohort of people born on or after January 1, 2024, so it will be applied from March 1, 2024 (first dose at two months of age)”, explains board.
The second approved file for an amount of 2,976,833 euros is processed for the purchase of 65,000 doses of the 20-valent pneumococcal conjugate vaccine that will be administered at age 65. “With a single dose, this vaccine provides adults with strong and significant protection against the serotypes responsible for the majority of pneumococcal diseases circulating worldwide,” the statement concludes.
2024-02-29 12:10:00
#Green #light #million #buy #vaccines #pneumococcus #babies #people #years #age
